NO20052231L - Assosiasjon mellom en parr-ligand og et antioksidantmiddel og anvendelse derav for behandling av obesitet - Google Patents

Assosiasjon mellom en parr-ligand og et antioksidantmiddel og anvendelse derav for behandling av obesitet

Info

Publication number
NO20052231L
NO20052231L NO20052231A NO20052231A NO20052231L NO 20052231 L NO20052231 L NO 20052231L NO 20052231 A NO20052231 A NO 20052231A NO 20052231 A NO20052231 A NO 20052231A NO 20052231 L NO20052231 L NO 20052231L
Authority
NO
Norway
Prior art keywords
association
parr
obesity
ligand
treatment
Prior art date
Application number
NO20052231A
Other languages
English (en)
Inventor
Pierre Renard
Catherine Dacquet
Louis Casteilla
Luc Penicaud
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of NO20052231L publication Critical patent/NO20052231L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen vedrører en assosiasjon inneholdende én eller flere ligander av peroksisom proliferatoraktiverte reseptorer og et antioksidantmiddel.Medikamenter.
NO20052231A 2002-10-11 2005-05-06 Assosiasjon mellom en parr-ligand og et antioksidantmiddel og anvendelse derav for behandling av obesitet NO20052231L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0212646A FR2845602B1 (fr) 2002-10-11 2002-10-11 Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
PCT/FR2003/002986 WO2004032967A1 (fr) 2002-10-11 2003-10-10 Association entre un ligand des ppar et un agent antioxydant et utilisation dans le traitement de l'obesite

Publications (1)

Publication Number Publication Date
NO20052231L true NO20052231L (no) 2005-05-06

Family

ID=32039639

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052231A NO20052231L (no) 2002-10-11 2005-05-06 Assosiasjon mellom en parr-ligand og et antioksidantmiddel og anvendelse derav for behandling av obesitet

Country Status (20)

Country Link
US (1) US20060002911A1 (no)
EP (2) EP1815858A3 (no)
JP (1) JP2006505548A (no)
KR (1) KR20050072759A (no)
CN (1) CN100571776C (no)
AR (1) AR041579A1 (no)
AU (1) AU2003299772C1 (no)
BR (1) BR0314539A (no)
CA (1) CA2501964A1 (no)
EA (1) EA010353B1 (no)
FR (1) FR2845602B1 (no)
GE (1) GEP20084462B (no)
MA (1) MA27402A1 (no)
MX (1) MXPA05003893A (no)
MY (1) MY140562A (no)
NO (1) NO20052231L (no)
NZ (2) NZ566708A (no)
PL (1) PL376045A1 (no)
UA (1) UA81132C2 (no)
WO (1) WO2004032967A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545799A (ja) * 2005-06-10 2008-12-18 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティー アンド アグリカルチュラル アンド メカニカル カレッジ 脂肪組織における末梢時計の調節
JP4863204B2 (ja) * 2005-06-15 2012-01-25 独立行政法人産業技術総合研究所 腎症関連疾患の診断方法及び診断キット
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20100022442A1 (en) * 2008-07-25 2010-01-28 Ambryx Biotechnology, Inc. Compositions and methods for increasing serum antioxidant concentrations, decreasing serum triglyceride levels, inhibiting insulin-receptor signaling activity, increasing serum ghrelin levels, and decreasing serum tnf-alpha levels
EA201101519A1 (ru) * 2009-05-11 2012-10-30 БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
BR112015025424A2 (pt) 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
JP6595478B2 (ja) 2013-09-04 2019-10-23 バーグ エルエルシー コエンザイムｑ１０の連続注入によるがんの治療方法
US10530115B2 (en) * 2014-10-02 2020-01-07 ETH Zürich Pulsed laser

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
WO1997028149A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
GB0019226D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
DE10044805A1 (de) * 2000-09-11 2002-04-04 Martin Klingenberg Verwendung von Coenzym Q zur Regulierung der Funktion der Entkopplerproteine
CZ301282B6 (cs) * 2000-10-26 2009-12-30 Fournier Laboratories Ireland Limited Farmaceutická smes fenofibrátu a koenzymu Q10 pro lécení endotelové dysfunkce
EP1357908A4 (en) * 2001-01-30 2009-07-15 Merck & Co Inc ACYL-SULFAMIDES FOR THE TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS
CA2437118A1 (en) * 2001-02-09 2002-08-22 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
BR0207285A (pt) * 2001-02-15 2004-02-10 Pfizer Producs Inc Agonistas de ppar
BR0207227A (pt) * 2001-02-15 2004-02-10 Pfizer Prod Inc Compostos receptores ativados proliferadores ppar

Also Published As

Publication number Publication date
EA200500609A1 (ru) 2005-10-27
JP2006505548A (ja) 2006-02-16
WO2004032967A1 (fr) 2004-04-22
CN100571776C (zh) 2009-12-23
AU2003299772B2 (en) 2009-03-12
NZ539331A (en) 2008-08-29
EP1815858A2 (fr) 2007-08-08
CA2501964A1 (fr) 2004-04-22
WO2004032967A8 (fr) 2005-05-06
MA27402A1 (fr) 2005-06-01
US20060002911A1 (en) 2006-01-05
UA81132C2 (en) 2007-12-10
CN1703244A (zh) 2005-11-30
AU2003299772A1 (en) 2004-05-04
EA010353B1 (ru) 2008-08-29
MY140562A (en) 2009-12-31
GEP20084462B (en) 2008-08-25
AR041579A1 (es) 2005-05-18
MXPA05003893A (es) 2005-08-03
EP1815858A3 (fr) 2007-12-19
EP1549348A1 (fr) 2005-07-06
NZ566708A (en) 2009-11-27
FR2845602A1 (fr) 2004-04-16
KR20050072759A (ko) 2005-07-12
AU2003299772C1 (en) 2009-08-27
FR2845602B1 (fr) 2005-07-08
PL376045A1 (en) 2005-12-12
BR0314539A (pt) 2005-07-26

Similar Documents

Publication Publication Date Title
NO20052231L (no) Assosiasjon mellom en parr-ligand og et antioksidantmiddel og anvendelse derav for behandling av obesitet
HUP0303915A2 (hu) Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációkra
ATE523497T1 (de) Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
DK1377280T3 (da) Fyldmidler som mæthedsfornemmelsesgivende midler
HK1121074A1 (en) Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
NO20052626D0 (no) Middel for forhindring eller behandling av neuropati
DE602004023342D1 (de) Siliconzusammensetzung und diese enthaltendes Papierbehandlungsmittel
NO20052476D0 (no) 2-alkyl-(2-amino-3-aryl-propionyl)-piperazinderivater og beslektede forbindelser som melanokortinreseptorligander for behandlingen av obesitet.
NO20072839L (no) 4-hydroksybenzomorfaner
DE602004007808D1 (de) Neue gamma secretase inhibitoren
NO20051521D0 (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
EP1476471A4 (en) FUNCTIONAL FOODS FOR THE TREATMENT, PROTECTION AND RESTORATION OF CONNECTIVE TISSUES
NO20054744L (no) Behandling av Alzheimers sykdom
DE60334592D1 (de) Differentialpumpvorrichtung und Belichtungsgerät
DE60239218D1 (de) Synergistische zusammensetzungen für die behandlung von saatgut
NO20044030L (no) Anvendelse av antitumor indolopyrrolocarbazolderivat og annet anticancer middel i kombinasjon
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
NO20031806D0 (no) Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati
ATE382778T1 (de) Pumpenkombination
ES2345882T3 (es) Nuevos compuestos y su uso como moduladores de ppar.
DK1558620T3 (da) Rutheniumkomplekser med anticancervirkning
SI1569634T1 (sl) Uporaba PPAR-alfa agonista in metformina za zdravljenje obezitete
DE60332860D1 (de) Neue verbindungen, die sich f r die behandlung von durch ppar vermittelten krankheiten eignen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application